Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | Q9HBH1 | 1/20 | 0.31 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132074 | 0.77 | FAAH (0.34) | — | |
| SCHEMBL4120704 | 0.73 | DPP4 (0.43) | ALDH1A1DPP4 | |
| SCHEMBL21325199 | 0.72 | DPP4 (0.33) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| SCHEMBL7333954 | 0.71 | ALDH1A1 (0.37) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| SCHEMBL4121226 | 0.71 | DPP4 (0.38) | DPP4 | |
| SCHEMBL12867291 | 0.70 | ALDH1A1 (0.38) | TSHRALDH1A1DPP4PDF | |
| SCHEMBL6799803 | 0.70 | DPP4 (0.36) | TSHRALDH1A1DPP4PDF | |
| SCHEMBL14108242 | 0.70 | ALDH1A1 (0.38) | TSHRALDH1A1DPP4PDF | |
| SCHEMBL4122456 | 0.69 | PIK3CD (0.33) | DPP4 | |
| SCHEMBL4132080 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0621867-B1 | NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-07 | — | — | EP | claimed |
| US-5538950-A | PEPTIDE DERIVATIVES AS HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-23 | — | — | US | claimed |
| EP-0621867-A1 | NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | claimed |
| WO-1993010144-A1 | NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-27 | — | — | WO | claimed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6087324-A | A WATER-INSOLUBLE OR A SLIGHTLY WATER-SOLUBLE POLYVALENT METAL SALT OF A WATER-SOLUBLE PHYSIOGICALLY ACTIVE PEPTIDE WHICH IS NOT AN ENDOTHELIN ANTAGONIST, AND A BIODEGRADABLE POLYMER SUCH AS COPOLYMER OF GLYCOLIC AND LACTIC ACID | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0621867-B1 | NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-5538950-A | PEPTIDE DERIVATIVES AS HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| WO-1993010144-A1 | NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | TSHR 2159/4885ALDH1A1 2741/4885NFKB1 367/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | TSHR 2159/4885ALDH1A1 2741/4885NFKB1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.